重大事件
即時報告
8-K
2026-07-23
Inhibikase Therapeutics 獲FDA孤兒藥資格 IKT-001治療肺動脈高壓
AI 繁中摘要
Inhibikase Therapeutics 公佈 FDA 授予 IKT-001 孤兒藥資格（ODD）用於治療肺動脈高壓（PAH）｜8-K 申報摘要
Inhibikase Therapeutics, Inc.（納斯達克：IKT）於 2026 年 7 月 23 日提交 8-K 表格，披露其領先候選藥物 IKT-001（伊馬替尼前藥）已獲美國 FDA 孤兒藥產品開發辦公室授予孤兒藥資格，用於治療肺動脈高壓（PAH）。PAH 是一種進展性、危及生命的罕見疾病，美國約有 5 萬名患者，目前存在高度未滿足的醫療需求。
CEO Mark Iwicki 表示，此項 ODD 是公司重要里程碑，標誌著 PAH 患者對新型治療的迫切需求。他指出，近期在美國胸科學會國際會議上發表的 IKT-001 臨床前數據顯示，該藥可改善肺血管及血流動力學指標，且相較於伊馬替尼甲磺酸鹽，胃腸道毒性風險較低。公司相信 IKT-001 有潛力成為首個每日一次的口服增殖抑制劑，為 PAH 患者帶來顯著益處。
孤兒藥資格可提供開發激勵措施，包括合資格臨床試驗成本的稅收抵免、部分 FDA 申請費豁免，以及獲得批准後長達七年的市場獨佔權。該資格適用於活性成分伊馬替尼，而非特定製劑。
Inhibikase 目前正在全球約 180 個中心進行第三期關鍵性臨床試驗 IMPROVE-PAH，評估 IKT-001 對 PAH 患者的療效與安全性。此次 ODD 授予有望加速開發進程，並提升該產品未來商業化的潛力，對投資者而言屬正面信號，但需注意臨床試驗結果及監管審批仍存在不確定性。
展開英文正文
EX-99.1 2 d121491dex991.htm EX-99.1 EX-99.1 Exhibit 99.1 Inhibikase Therapeutics Announces FDA Orphan Drug Designation Granted to IKT-001 for the Treatment of PAH WILMINGTON, Del., July 23, 2026 — Inhibikase Therapeutics, Inc. (Nasdaq: IKT) (“Inhibikase” or “Company”), a clinical-stage pharmaceutical company developing IKT-001 for Pulmonary Arterial Hypertension (“PAH”), today announced that the U.S. Food and Drug Administration (“FDA”) has granted Orphan Drug Designation (“ODD”) to its lead product candidate IKT-001, a prodrug of imatinib mesylate, for the treatment of PAH. “The grant of Orphan Drug Designation for IKT-001 by FDA is another important milestone for Inhibikase and reflects the high unmet medical need among the approximately 50,000 people suffering from PAH in the United States,” said Mark Iwicki, Chief Executive Officer of Inhibikase. “PAH is a progressive and life-threatening disease with substantially diminished quality of life which is caused by the abnormal proliferation of vascular cells in the lung. Recently, presentations of IKT-001 pre-clinical data at the American Thoracic Society International Conference in Orlando demonstrated improvements in pulmonary vascular and hemodynamic markers of PAH, together with a lower potential for GI toxicity compared to imatinib mesylate, and we believe that IKT-001’s potential to be the first once-daily oral proliferative may offer significant potential benefits to the PAH patient population.” Orphan Drug Designation was granted by the FDA’s Office of Orphan Products Development. As noted by the FDA, orphan designation applies to the active moiety of IKT-001, imatinib, rather than a specific formulation. ODD also provides potential development incentives, including eligibility for tax credits on qualified clinical trial costs, exemption from certain FDA user fees, and the potential for seven years of market exclusivity upon regulatory approval. Orphan Drug Designation is granted to investigational therapies intended to treat rare diseases affecting fewer than 200,000 patients in the United States. About Inhibikase Inhibikase Therapeutics, Inc. (Nasdaq: IKT) is a clinical-stage pharmaceutical company developing therapeutics to modify the course of cardiopulmonary diseases, namely, Pulmonary Arterial Hypertension (“PAH”), in which aberrant signaling through type III receptor tyrosine kinases, including platelet derived growth factor receptors and a stem cell factor receptor, known as “c-Kit,” has been implicated. Our lead product candidate is IKT-001, a prodrug of imatinib mesylate (“imatinib”), for PAH which is an orphan indication. Imatinib was first approved in the United States in 2001 for various cancers and blood disorders and, following more than 20 years of clinical use, has a well-characterized safety profile with the first reported use of imatinib in PAH occurring in 2005. PAH is a progressive, life-threatening disease characterized by pulmonary vascular remodeling and elevated pulmonary vascular resistance that affects approximately 50,000 Americans. Our single pivotal Phase 3 clinical study in PAH in approximately 180 sites around the world, named IMPROVE-PAH (IKT-001 for Measuring Pulmonary Vascular Resistance and Outcome Variables in a Phase 3 Evaluation of PAH), is actively enrolling patients. Forward-Looking Statements This press release contains “forward-looking statements” within the meaning of the Private Securities Litigation Reform Act of 1995. Forward-looking terminology such as “believes,” “expects,” “may,” “will,” “should,” “anticipates,” “plans,” or similar expressions or the negative of these terms and similar expressions are intended to identify forward-looking statements. These forward-looking statements include, but are not limited to, statements that express the Company’s beliefs about the potential benefits of Orphan Drug Designation. These forward-looking statements are based on Inhibikase’s current expectations and assumptions. Such statements are subject to certain risks and uncertainties, which could cause Inhibikase’s actual results to differ materially from those anticipated by the forward-looking statements. Important factors that could cause actual results to differ materially from those in the forward-looking statements include our ability to realize any of the potential benefits of Orphan Drug Designation, as well as such other factors that are included in our periodic reports on Form 10-K and Form 10-Q that we file with the U.S. Securities and Exchange Commission. Any forward-looking statement in this release speaks only as of the date of this release. Inhibikase undertakes no obligation to publicly update or revise any forward-looking statement, whether as a result of new information, future developments or otherwise, except as may be required by any applicable securities laws. Contacts: Investor Relations: Michael Moyer LifeSci Advisors [email protected]